You are here

Article Text

Article menu
Download PDFPDF
Colorectal
Leading article
Infliximab in acute severe colitis: getting the right dose
  1. Joseph Fiske1,
  2. Thomas Conley1,
  3. Shaji Sebastian2,
  4. Sreedhar Subramanian1
  1. 1 Department of Gastroenterology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK
  2. 2 IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK
  1. Correspondence to Dr Sreedhar Subramanian, Gastroenterology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool HU3 2JZ, UK; sreedhar.subramanian{at}rlbuht.nhs.uk

Abstract

Acute severe colitis is a medical emergency and requires prompt treatment with intravenous steroids. Infliximab is typically used as rescue therapy in those who fail to respond to corticosteroids. This article outlines the altered pharmacokinetics of infliximab in acute severe UC and summarised the latest published data surrounding accelerated infliximab dosing.

  • infliximab
  • ulcerative colitis
  • clinical decision making
  • inflammatory bowel disease

https://doi.org/10.1136/flgastro-2020-101407

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors JF and SrS were involved in drafting and final revision of the manuscript. All authors involved (JF, TC, SrS and ShS) were involved in editing and approval of the final version of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests SrS has received speaker fee from Abbvie, Dr Falk Pharma, Shire, Takeda, Janssen and received educational grant from Abbvie, Actavis, Janssen, Takeda, Dr Falk Pharma and is an advisory board member for Abbvie, Dr Falk Pharma and Vifor Pharma.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles